Startups

Baltimore-based AsclepiX Therapeutics raises $5M

The Johns Hopkins spinout is developing a new treatment for leading causes of blindness.

Inside FastForward 1812, an East Baltimore-based incubator home that is based in East Baltimore. (Photo by Stephen Babcock)

Johns Hopkins spinout AsclepiX Therapeutics raised $5 million in new funding that will assist in development of new treatment for eye diseases that are leading causes of blindness in adults.
The convertible note round was led by Barer & Son Capital, with participation from Rapha Capital Management, Salem Partners, TEDCO, and Piedmont Capital Partners. It brings the company’s total raised to $11 million.
The company was founded by Johns Hopkins biomedical engineering professors Aleksander Popel and Jordan J. Green, who developed peptide products that form the foundation of the company’s treatments.
With a team of four people at JHU’s FastForward space in Remington’s R. House, Ascelpix is developing a treatment for diseases called diabetic macular edema and wet age-related macular degeneration. According to the company, the number of people with the treatment is expected to reach 7 million by 2020.
Currently available treatments require an injection into the eye once a month for several months. AsclepiX Therapeutics’ first treatment, called ATX107, offers the potential for treating the diseases with fewer injections.
“In extensive animal testing, AXT107 was safe and superior to current approved therapies in preventing and even reversing progressive pathologic changes in the retina with just two to three injections per year, a clear benefit in longer duration and less frequent dosing compared to those currently approved therapies,” said AsclepiX Therapeutics CEO Wendy Perrow.
The funding will assist the company as it seeks to complete its application for investigational new drug status with the U.S. Food and Drug Administration. The company is also planning for clinical trials for patients with diabetic macular edema and wet age-related macular degeneration.
With the investment, Barer and Sons Managing Partner Josh Barer, Rapha Capital Management Managing Partner Kevin Slawin, and Sapna Srivastava are joining the company’s board.
“Vision loss is a devastating complication of several common diseases, including diabetes. We’re excited at the potential of AXT107 to help millions avoid this difficult disability while requiring less frequent therapeutic interventions by their ophthalmologists,” Slawin said in a statement.

Before you go...

Please consider supporting Technical.ly to keep our independent journalism strong. Unlike most business-focused media outlets, we don’t have a paywall. Instead, we count on your personal and organizational support.

Our services Preferred partners The journalism fund
Engagement

Join our growing Slack community

Join 5,000 tech professionals and entrepreneurs in our community Slack today!

Trending

Baltimore is setting a national standard for diversifying its economy

19 tech and entrepreneurship events to check out before the holidays

Tech lab space opening in new 4MLK building, thanks to $2M in public funds

EDA officials are ‘hopeful’ Tech Hubs program will live on under Trump

Technically Media